Hans L Tillmann

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
  2. doi request reprint Emerging pipeline drugs for hepatitis B infection
    Natravis Cox
    Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Emerg Drugs 16:713-29. 2011
  3. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
  4. doi request reprint Vitamins? The magic bullet against hepatitis C
    Hans L Tillmann
    Gastroenterology Division, Duke Clinical Research Institute Hepatology Gastroenterology Research, Duke University, Durham, NC 27708, USA
    Expert Rev Anti Infect Ther 10:1273-7. 2012
  5. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
  6. doi request reprint A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Gastroenterology 139:1586-92, 1592.e1. 2010
  7. doi request reprint Use of thrombopoietic agents for the thrombocytopenia of liver disease
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715 7969, USA
    Semin Hematol 47:266-73. 2010
  8. doi request reprint Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment
    H L Tillmann
    Medizinische Hochschule Hannover, Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany
    J Viral Hepat 18:252-61. 2011
  9. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
  10. doi request reprint Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011

Collaborators

Detail Information

Publications27

  1. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
    ..06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high-density lipoprotein cholesterol (P = 0.78) and apolipoprotein C-III (P = 0.74) did not vary by rs12979860 genotype...
  2. doi request reprint Emerging pipeline drugs for hepatitis B infection
    Natravis Cox
    Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Emerg Drugs 16:713-29. 2011
    ..The long-term efficacy of combinations of IFN and/or nucleos(t)ide analogs might achieve antiviral synergy, preventing drug resistance and clearing viral covalently close circular DNA and infected cells...
  3. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
    ..Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment...
  4. doi request reprint Vitamins? The magic bullet against hepatitis C
    Hans L Tillmann
    Gastroenterology Division, Duke Clinical Research Institute Hepatology Gastroenterology Research, Duke University, Durham, NC 27708, USA
    Expert Rev Anti Infect Ther 10:1273-7. 2012
    ..Vitamin D had repeatedly been reported to be associated with response to HCV therapy. It will be interesting to see whether vitamins such as B12 and D will remain relevant in the light of direct antivirals...
  5. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
    ..Here we analyzed the association of steatosis with IL28B genotype in treatment naïve patients with CHC...
  6. doi request reprint A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Gastroenterology 139:1586-92, 1592.e1. 2010
    ..We analyzed the association between IL28B and the clinical presentation of acute hepatitis C virus (HCV) infection in a homogeneous population...
  7. doi request reprint Use of thrombopoietic agents for the thrombocytopenia of liver disease
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715 7969, USA
    Semin Hematol 47:266-73. 2010
    ..A current phase III study is currently evaluating whether this treatment allows successful outcomes and sustained viral eradication...
  8. doi request reprint Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment
    H L Tillmann
    Medizinische Hochschule Hannover, Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany
    J Viral Hepat 18:252-61. 2011
    ..This may suggest that HCV either may not be involved in QoL impairment or may induce a process which persists after viral clearance in some patients...
  9. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  10. doi request reprint Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
    ..Conclusion: Two ITPA variants were strongly associated with protection against treatment-related anemia in patients with genotype 2/3 HCV, but they did not decrease the need for RBV dose reduction or increase the rate of SVR...
  11. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
    ..We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia...
  12. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
    ..Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined...
  13. doi request reprint High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    Hepatology 53:1809-18. 2011
    ..A model averaging approach for identified peptides resulted in an AUROC of 0.86 in the validation cohort, and correctly identified virologic response in 71% of patients without the favorable IL28B "responder" genotype...
  14. pmc Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C
    Derek D Cyr
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e21854. 2011
    ..To gain further insight into IL28B function we assessed the association of rs12979860 with expression of protein quantitative traits (pQTL analysis) generated using open-platform proteomics in serum from patients...
  15. doi request reprint Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Unit and DUMC, Durham, NC, USA
    Antivir Ther 16:1341-6. 2011
    ..Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients...
  16. doi request reprint Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 139:120-9.e18. 2010
    ..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
  17. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
  18. ncbi request reprint Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27715 7969, USA
    Curr Gastroenterol Rep 11:5-14. 2009
    ..Phase 3 studies are currently evaluating whether initiating and maintaining antiviral therapy with eltrombopag will lead to an increase in sustained virologic response in chronic hepatitis C infection...
  19. doi request reprint HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome
    Benjamin Heidrich
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Int 32:1415-25. 2012
    ..The aim of this study was to investigate the role of HBeAg in patients co-infected with the hepatitis D virus (HDV)...
  20. doi request reprint Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
    Hans L Tillmann
    Division of Gastroenterology, GI Hepatology Research Program, Duke Clinical Research Institute, Durham, NC, USA
    Liver Int 32:544-53. 2012
    ..Thus, in the absence of solid evidence based data, the hepatologists could treat their patients with severe acute hepatitis B with lamivudine or the most potent antivirals entecavir or tenofovir...
  21. doi request reprint Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues
    Jerzy Jaroszewicz
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Antivir Ther 16:915-24. 2011
    ..Serum interferon-inducible protein-10 (IP-10) has been associated with treatment response in hepatitis C, but data in chronic hepatitis B are lacking. Here, we aimed to investigate potential factors predictive for HBsAg loss...
  22. ncbi request reprint Donor origin of de novo hepatocellular carcinoma in hepatic allografts
    Peer Flemming
    Institut fur Pathologie, Medizinische Hochschule Hannover, Hannover, Germany
    Transplantation 76:1625-7. 2003
    ..Because recent data demonstrated a mixed hepatocellular chimerism caused by the integration of host-derived stem cells, a study was conducted on the origin of tumor cells in de novo HCC...
  23. ncbi request reprint Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation
    Jens Rosenau
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Transpl 13:367-73. 2007
    ..Further studies should address the question, of whether the use of potent adjuvant systems results in higher response rates...
  24. ncbi request reprint Longer survival of liver transplant recipients with hepatitis virus coinfections
    Kinan Rifai
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Clin Transplant 21:258-64. 2007
    ..Thus, viral coinfections may be associated with ameliorated courses of diseases under certain conditions...
  25. doi request reprint Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation
    Nazanin Hooman
    Department of Gastroenterology, Medizinische Hochschule Hannover, Hannover, Germany
    Liver Transpl 14:435-42. 2008
    ..That is, IM HBIG is not dose-saving; however, it may be cost-effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dosing schemes...
  26. ncbi request reprint A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels
    Johannes Wiegand
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
    Antivir Ther 13:547-54. 2008
    ..As quantitative assays for HBsAg recently became available, we have investigated whether quantitative HBsAg measurements can substitute for hepatitis B virus (HBV) DNA quantification in treatment monitoring...
  27. ncbi request reprint Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency
    Hans L Tillmann
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Liver Transpl 9:191-6. 2003
    ..Adefovir dipivoxil resulted in significant clinical improvement in this patient with hepatitis B virus-induced fibrosing cholestatic hepatitis, despite the presence of renal impairment and lamivudine resistance...